Marpai (MRAI) Competitors

$0.27 +0.02 (+10.04%)

As of 01:01 PM Eastern

MRAI vs. PIII, CCM, BMGL, ACON, and ADVB

Should you be buying Marpai stock or one of its competitors? The main competitors of Marpai include P3 Health Partners (PIII), Concord Medical Services (CCM), Basel Medical Group (BMGL), Aclarion (ACON), and Advanced Biomed (ADVB). These companies are all part of the "healthcare" industry.

How does Marpai compare to P3 Health Partners?

Marpai (NASDAQ:MRAI) and P3 Health Partners (NASDAQ:PIII) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

: P3 Health Partners has a net margin of -10.14% compared to Marpai's net margin of -85.70%. Marpai's return on equity of 0.00% beat P3 Health Partners' return on equity.
Company Net Margins Return on Equity Return on Assets
Marpai -85.70% N/A -100.23%
P3 Health Partners -10.14% -302.33% -20.72%
: P3 Health Partners has a consensus price target of $3.50, indicating a potential upside of 21.11%. Given P3 Health Partners' stronger consensus rating and higher possible upside, analysts clearly believe P3 Health Partners is more favorable than Marpai.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Marpai
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
P3 Health Partners
1 Sell rating(s)

2 Hold rating(s)

1 Buy rating(s)

0 Strong Buy rating(s)
2.00
: In the previous week, Marpai had 1 more articles in the media than P3 Health Partners. MarketBeat recorded 1 mentions for Marpai and 0 mentions for P3 Health Partners. Marpai's average media sentiment score of 1.08 beat P3 Health Partners' score of 0.00 indicating that Marpai is being referred to more favorably in the media.
Company Overall Sentiment
Marpai Positive
P3 Health Partners Neutral
: Marpai has a beta of 4.39, indicating that its share price is 339% more volatile than the S&P 500. Comparatively, P3 Health Partners has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.
: 49.8% of Marpai shares are owned by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are owned by institutional investors. 46.1% of Marpai shares are owned by company insiders. Comparatively, 17.8% of P3 Health Partners shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
: Marpai has higher earnings, but lower revenue than P3 Health Partners. Marpai is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Marpai $34.87M 0.20 -$28.75M -$0.95 N/A
P3 Health Partners $1.46B 0.01 -$147.95M -$45.20 N/A

Company	Net Margins	Return on Equity	Return on Assets
Marpai	-85.70%	N/A	-100.23%
P3 Health Partners	-10.14%	-302.33%	-20.72%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Company	Overall Sentiment
Marpai	Positive
P3 Health Partners	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marpai	$34.87M	0.20	-$28.75M	-$0.95	N/A
P3 Health Partners	$1.46B	0.01	-$147.95M	-$45.20	N/A

Summary

Marpai beats P3 Health Partners on 9 of the 16 factors compared between the two stocks.

How does Marpai compare to Concord Medical Services?

Concord Medical Services (NYSE:CCM) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

: Concord Medical Services has a net margin of 0.00% compared to Marpai's net margin of -85.70%.
Company Net Margins Return on Equity Return on Assets
Concord Medical Services N/A N/A N/A
Marpai -85.70% N/A -100.23%
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Concord Medical Services
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Marpai
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: In the previous week, Concord Medical Services had 8 more articles in the media than Marpai. MarketBeat recorded 9 mentions for Concord Medical Services and 1 mentions for Marpai. Marpai's average media sentiment score of 1.08 beat Concord Medical Services' score of 0.15 indicating that Marpai is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Concord Medical Services
0 Very Positive mention(s)
0 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Marpai
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Concord Medical Services has a beta of -1.09, suggesting that its stock price is 209% less volatile than the S&P 500. Comparatively, Marpai has a beta of 4.39, suggesting that its stock price is 339% more volatile than the S&P 500.
: 49.8% of Marpai shares are owned by institutional investors. 46.5% of Concord Medical Services shares are owned by company insiders. Comparatively, 46.1% of Marpai shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
: Concord Medical Services has higher revenue and earnings than Marpai.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Concord Medical Services $65.85M 0.31 -$13.27M N/A N/A
Marpai $34.87M 0.20 -$28.75M -$0.95 N/A

Company	Net Margins	Return on Equity	Return on Assets
Concord Medical Services	N/A	N/A	N/A
Marpai	-85.70%	N/A	-100.23%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Concord Medical Services	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Concord Medical Services	0 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Marpai	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Concord Medical Services	$65.85M	0.31	-$13.27M	N/A	N/A
Marpai	$34.87M	0.20	-$28.75M	-$0.95	N/A

Summary

Concord Medical Services beats Marpai on 8 of the 11 factors compared between the two stocks.

How does Marpai compare to Basel Medical Group?

Basel Medical Group (NASDAQ:BMGL) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

: Basel Medical Group has a net margin of 0.00% compared to Marpai's net margin of -85.70%.
Company Net Margins Return on Equity Return on Assets
Basel Medical Group N/A N/A N/A
Marpai -85.70% N/A -100.23%
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Basel Medical Group
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Marpai
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: In the previous week, Marpai had 1 more articles in the media than Basel Medical Group. MarketBeat recorded 1 mentions for Marpai and 0 mentions for Basel Medical Group. Marpai's average media sentiment score of 1.08 beat Basel Medical Group's score of 0.00 indicating that Marpai is being referred to more favorably in the news media.
Company Overall Sentiment
Basel Medical Group Neutral
Marpai Positive
: Basel Medical Group has a beta of 0.07, suggesting that its stock price is 93% less volatile than the S&P 500. Comparatively, Marpai has a beta of 4.39, suggesting that its stock price is 339% more volatile than the S&P 500.
: 49.8% of Marpai shares are owned by institutional investors. 46.1% of Marpai shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
: Basel Medical Group has higher earnings, but lower revenue than Marpai.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Basel Medical Group $8.90M 1.28 -$9.50M N/A N/A
Marpai $34.87M 0.20 -$28.75M -$0.95 N/A

Company	Net Margins	Return on Equity	Return on Assets
Basel Medical Group	N/A	N/A	N/A
Marpai	-85.70%	N/A	-100.23%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Basel Medical Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Overall Sentiment
Basel Medical Group	Neutral
Marpai	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Basel Medical Group	$8.90M	1.28	-$9.50M	N/A	N/A
Marpai	$34.87M	0.20	-$28.75M	-$0.95	N/A

Summary

Marpai beats Basel Medical Group on 6 of the 11 factors compared between the two stocks.

How does Marpai compare to Aclarion?

Aclarion (NASDAQ:ACON) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

: Aclarion has higher earnings, but lower revenue than Marpai. Marpai is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aclarion $80K 98.40 -$7.23M -$17.01 N/A
Marpai $34.87M 0.20 -$28.75M -$0.95 N/A
: Marpai has a net margin of -85.70% compared to Aclarion's net margin of -9,517.11%. Marpai's return on equity of 0.00% beat Aclarion's return on equity.
Company Net Margins Return on Equity Return on Assets
Aclarion -9,517.11% -52.31% -49.79%
Marpai -85.70% N/A -100.23%
: Aclarion has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, Marpai has a beta of 4.39, suggesting that its share price is 339% more volatile than the S&P 500.
: In the previous week, Aclarion had 1 more articles in the media than Marpai. MarketBeat recorded 2 mentions for Aclarion and 1 mentions for Marpai. Marpai's average media sentiment score of 1.08 beat Aclarion's score of 0.00 indicating that Marpai is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aclarion
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Marpai
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aclarion
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Marpai
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: 7.5% of Aclarion shares are owned by institutional investors. Comparatively, 49.8% of Marpai shares are owned by institutional investors. 0.8% of Aclarion shares are owned by insiders. Comparatively, 46.1% of Marpai shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80K	98.40	-$7.23M	-$17.01	N/A
Marpai	$34.87M	0.20	-$28.75M	-$0.95	N/A

Company	Net Margins	Return on Equity	Return on Assets
Aclarion	-9,517.11%	-52.31%	-49.79%
Marpai	-85.70%	N/A	-100.23%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclarion	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Marpai	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Marpai beats Aclarion on 9 of the 14 factors compared between the two stocks.

How does Marpai compare to Advanced Biomed?

Advanced Biomed (NASDAQ:ADVB) and Marpai (NASDAQ:MRAI) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

: Advanced Biomed has higher earnings, but lower revenue than Marpai. Marpai is trading at a lower price-to-earnings ratio than Advanced Biomed, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Advanced Biomed N/A N/A -$3.26M $3.80 1.81
Marpai $34.87M 0.20 -$28.75M -$0.95 N/A
: Advanced Biomed has a net margin of 0.00% compared to Marpai's net margin of -85.70%. Advanced Biomed's return on equity of 92.11% beat Marpai's return on equity.
Company Net Margins Return on Equity Return on Assets
Advanced Biomed N/A 92.11% 58.03%
Marpai -85.70% N/A -100.23%
: Advanced Biomed has a beta of 0.56, suggesting that its share price is 44% less volatile than the S&P 500. Comparatively, Marpai has a beta of 4.39, suggesting that its share price is 339% more volatile than the S&P 500.
: In the previous week, Advanced Biomed and Advanced Biomed both had 1 articles in the media. Advanced Biomed's average media sentiment score of 1.29 beat Marpai's score of 1.08 indicating that Advanced Biomed is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Advanced Biomed
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Marpai
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Advanced Biomed
1 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.00
Marpai
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: 49.8% of Marpai shares are owned by institutional investors. 34.4% of Advanced Biomed shares are owned by insiders. Comparatively, 46.1% of Marpai shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Advanced Biomed	N/A	N/A	-$3.26M	$3.80	1.81
Marpai	$34.87M	0.20	-$28.75M	-$0.95	N/A

Company	Net Margins	Return on Equity	Return on Assets
Advanced Biomed	N/A	92.11%	58.03%
Marpai	-85.70%	N/A	-100.23%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Advanced Biomed	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Marpai	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Advanced Biomed	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Marpai	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Advanced Biomed beats Marpai on 8 of the 12 factors compared between the two stocks.

Get Marpai News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MRAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MRAI vs. The Competition

Export

Metric	Marpai	health & allied services, not elsewhere classified Industry	Business Sector	NASDAQ Exchange
Market Cap	$6.86M	$79.31M	$6.40B	$11.77B
Dividend Yield	N/A	N/A	3.07%	5.26%
P/E Ratio	-0.10	0.74	21.41	23.23
Price / Sales	0.20	0.14	431.77	75.49
Price / Cash	N/A	4.19	23.12	53.90
Price / Book	-0.16	0.15	5.84	6.69
Net Income	-$28.75M	$25.15M	$200.90M	$332.64M
7 Day Performance	4.88%	1.66%	1.27%	2.01%
1 Month Performance	-17.97%	-12.31%	7.46%	9.19%
1 Year Performance	-74.22%	-31.34%	56.26%	39.59%

Marpai Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MRAI Marpai	N/A	$0.27 +10.0%	N/A	N/A	$6.86M	$34.87M	N/A	150	Positive News Gap Up
PIII P3 Health Partners	1.7363 of 5 stars	$2.80 -3.1%	$3.50 +25.0%	N/A	$20.19M	$1.46B	N/A	500
CCM Concord Medical Services	0.2611 of 5 stars	$3.82 +0.4%	N/A	N/A	$16.60M	$365.76M	N/A	970	Earnings Report Gap Down
BMGL Basel Medical Group	0.2139 of 5 stars	$0.56 -10.1%	N/A	N/A	$10.52M	$8.90M	N/A	36	Gap Down
ACON Aclarion	0.1327 of 5 stars	$3.26 -3.3%	N/A	N/A	$7.43M	$80K	N/A	7

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MRAI) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Marpai (MRAI) Competitors

MRAI vs. PIII, CCM, BMGL, ACON, and ADVB

How does Marpai compare to P3 Health Partners?

Summary

How does Marpai compare to Concord Medical Services?

Summary

How does Marpai compare to Basel Medical Group?

Summary

How does Marpai compare to Aclarion?

Summary

How does Marpai compare to Advanced Biomed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRAI vs. The Competition

Marpai Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Marpai (MRAI) Competitors

MRAI vs. PIII, CCM, BMGL, ACON, and ADVB

How does Marpai compare to P3 Health Partners?

Summary

How does Marpai compare to Concord Medical Services?

Summary

How does Marpai compare to Basel Medical Group?

Summary

How does Marpai compare to Aclarion?

Summary

How does Marpai compare to Advanced Biomed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MRAI vs. The Competition

Marpai Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools